689 related articles for article (PubMed ID: 22252844)
1. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.
Bazzi C; Rizza V; Casellato D; Stivali G; Rachele G; Napodano P; Olivieri G; Gallieni M; D'Amico G
J Nephrol; 2012; 25(5):810-8. PubMed ID: 22252844
[TBL] [Abstract][Full Text] [Related]
2. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
[TBL] [Abstract][Full Text] [Related]
3. In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression.
Bazzi C; Rizza V; Raimondi S; Casellato D; Napodano P; D'Amico G
Clin J Am Soc Nephrol; 2009 May; 4(5):929-35. PubMed ID: 19406958
[TBL] [Abstract][Full Text] [Related]
4. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China.
Lv J; Zhang H; Zhou Y; Li G; Zou W; Wang H
Nephrology (Carlton); 2008 Jun; 13(3):242-6. PubMed ID: 18221258
[TBL] [Abstract][Full Text] [Related]
5. Predictors for progression in immunoglobulin A nephropathy with significant proteinuria.
Hwang HS; Kim BS; Shin YS; Yoon HE; Song JC; Choi BS; Park CW; Yang CW; Kim YS; Bang BK
Nephrology (Carlton); 2010 Mar; 15(2):236-41. PubMed ID: 20470285
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
7. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy.
Peters HP; van den Brand JA; Wetzels JF
Neth J Med; 2009 Feb; 67(2):54-61. PubMed ID: 19299847
[TBL] [Abstract][Full Text] [Related]
8. A predictive clinical grading system for immunoglobulin A nephropathy by combining proteinuria and estimated glomerular filtration rate.
Okonogi H; Utsunomiya Y; Miyazaki Y; Koike K; Hirano K; Tsuboi N; Suzuki T; Hara Y; Ogura M; Hosoya T; Kawamura T
Nephron Clin Pract; 2011; 118(3):c292-300. PubMed ID: 21212693
[TBL] [Abstract][Full Text] [Related]
9. Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment.
de Goeij MC; Liem M; de Jager DJ; Voormolen N; Sijpkens YW; Rotmans JI; Boeschoten EW; Dekker FW; Grootendorst DC; Halbesma N;
Nephron Clin Pract; 2012; 121(1-2):c73-82. PubMed ID: 23128440
[TBL] [Abstract][Full Text] [Related]
10. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
Pozzi C; Andrulli S; Pani A; Scaini P; Roccatello D; Fogazzi G; Pecchini P; Rustichelli R; Finocchiaro P; Del Vecchio L; Locatelli F
J Nephrol; 2013; 26(1):86-93. PubMed ID: 22460183
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.
Chen J; Xu H; Peng Z; Lin L; Li C; Zhu X; Liu S
Clin Exp Nephrol; 2020 Jan; 24(1):73-81. PubMed ID: 31605314
[TBL] [Abstract][Full Text] [Related]
12. Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease.
Ekart R; Ferjuc A; Furman B; Gerjevič Š; Bevc S; Hojs R
Ther Apher Dial; 2013 Aug; 17(4):363-7. PubMed ID: 23931872
[TBL] [Abstract][Full Text] [Related]
13. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population.
Le W; Liang S; Hu Y; Deng K; Bao H; Zeng C; Liu Z
Nephrol Dial Transplant; 2012 Apr; 27(4):1479-85. PubMed ID: 21965586
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
Soleymanian T; Najafi I; Salimi BH; Broomand B
Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
[TBL] [Abstract][Full Text] [Related]
15. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
[TBL] [Abstract][Full Text] [Related]
16. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification).
Edström Halling S; Söderberg MP; Berg UB
Nephrol Dial Transplant; 2012 Feb; 27(2):715-22. PubMed ID: 21750154
[TBL] [Abstract][Full Text] [Related]
17. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
Shi X; Chen X; Liu S; Zhuang Y; Zhang Y
Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):399-403. PubMed ID: 12137603
[TBL] [Abstract][Full Text] [Related]
18. Soluble interleukin-2 receptor alfa predicts renal outcome in IgA nephropathy.
Lundberg S; Lundahl J; Gunnarsson I; Sundelin B; Jacobson SH
Nephrol Dial Transplant; 2012 May; 27(5):1916-23. PubMed ID: 21940483
[TBL] [Abstract][Full Text] [Related]
19. Impact of the apolipoprotein B/apolipoprotein A-I ratio on renal outcome in immunoglobulin A nephropathy.
Lundberg S; Gunnarsson I; Jacobson SH
Scand J Urol Nephrol; 2012 Apr; 46(2):148-55. PubMed ID: 22214235
[TBL] [Abstract][Full Text] [Related]
20. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
